| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT04825275 |
| P6099 | clinical trial phase | phase I clinical trial | Q5452194 |
| P17 | country | United States of America | Q30 |
| P582 | end time | 2023-05-01 | |
| P2899 | minimum age | 18 | |
| P1132 | number of participants | 10 | |
| P4844 | research intervention | antifungal | Q578726 |
| myristic acid | Q422658 | ||
| enzyme inhibitor | Q427492 | ||
| antiparasitic | Q581102 | ||
| antiprotozoal | Q582559 | ||
| posaconazole | Q906453 | ||
| mechanism of action | Q3271540 | ||
| hormone antagonist | Q16875676 | ||
| hormones, hormone substitutes, and hormone antagonists | Q50430050 | ||
| trypanocidal agent | Q50430185 | ||
| steroid synthesis inhibitor | Q50430472 | ||
| cytochrome P-450 enzyme inhibitors | Q50430501 | ||
| P8005 | research subject recruitment status | recruiting | Q76649708 |
| P580 | start time | 2022-02-08 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial |
Search more.